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The pathogenic process responsible for the loss of dopaminergic neurons within the substantia nigra of patients with
Parkinson disease (PD) is poorly understood. Current research supports the involvement of ﬁbroblast growth factor
(FGF20) in the survival of dopaminergic cells. FGF20 is a neurotrophic factor that is preferentially expressed within
the substantia nigra of rat brain. The human homologue has been mapped to 8p21.3-8p22, which is within an area
of PD linkage revealed through our published genomic screen. To test whether FGF20 inﬂuences risk of PD, we
genotyped ﬁve single-nucleotide polymorphisms (SNPs) lying within the FGF20 gene, in a large family study. We
analyzed our sample (644 families) through use of the pedigree disequilibrium test (PDT), the genotype PDT, the
multilocus-genotype PDT, and the family-based association test to assess association between risk of PD and alleles,
genotypes, multilocus genotypes, and haplotypes.We discovered a highly signiﬁcant association of PDwith one intronic
SNP, rs1989754 ( ), and two SNPs, rs1721100 ( ) and ss20399075 ( ), located in the 3′Pp .0006 Pp .02 Pp .0008
regulatory region in our overall sample. Furthermore, we detected a haplotype (A-G-C-C-T) that is positively associated
with risk of PD ( ), whereas a second haplotype (A-G-G-G-C) was found to be negatively associated withPp .0003
risk of PD ( ). Our results strongly support FGF20 as a risk factor for PD.Pp .0009
Introduction
Parkinson disease (PD [MIM 168600]) is a late-onset
neurodegenerative disorder that typically develops in the
5th or 6th decade of life and affects more than one
million Americans. The inability to control movement
in patients with PD results from severe loss of dopa-
minergic neurons within the substantia nigra (SN). The
mechanism causing dopaminergic cell death in PD has
not been deﬁned, although it is generally accepted that
environmental and genetic sources act together in the
disease cascade.
In familial PD, 11 loci, including 5 known genes (par-
kin, a-synuclein, UCH-L1, DJ-1, and NR4A2) have
been identiﬁed as causative for the Mendelian patterns
of PD (see Dekker 2003). Several genomic screens have
demonstrated areas of linkage that may harbor impor-
tant genetic risk factors for the common, late-onset form
of PD (Scott et al. 2001; Pankratz et al. 2003). The
strongest linkage result overall in our study was ob-
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tained on chromosome 8p (LOD score 2.2 at D8S520)
(Scott et al. 2001). In an attempt to identify physical
and biological candidate genes in this region that inﬂu-
ence risk of PD, we chose to examine ﬁbroblast growth
factor 20 (FGF20), since it is located ∼6.2 Mb from
peak marker D8S520 on 8p21.3-p22 (Kirikoshi et al.
2000), and its encoded protein exerts strong neuro-
trophic properties within brain tissue (Jeffers et al.
2001).
FGF20 is a member of the highly conserved growth
factor polypeptides that regulate central nervous de-
velopment and function (Jeffers et al. 2001; Dono
2003). Speciﬁcally, FGF20 is a neurotrophic factor that
is preferentially expressed within dopaminergic neurons
of the midbrain SN within rat brain (Ohmachi et al.
2000) and is also expressed in human cerebellum and
SN tissue (Jeffers et al. 2001; Hauser et al. 2003). Ev-
idence suggests that expression of FGF20 signiﬁcantly
enhances the survival of rat midbrain dopaminergic neu-
rons and that this activity operates by way of binding
to the FGF receptor FGFR-1c (Ohmachi et al. 2003).
Furthermore, a recent study demonstrated that FGF2,
closely related to FGF20, added to cultured rat ventral
midbrain dopaminergic neurons induces upregulation
of a-synuclein (Rideout et al. 2003). Therefore, FGF20
presents as a strong biological and positional candidate
for investigation of PD susceptibility.
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Material and Methods
Samples
Affected individuals and familymemberswere collected
by the Duke Center for Human Genetics (DCHG)Morris
K. Udall Parkinson Disease Research Center of Excellence
family ascertainment core and the 13 centers of the Par-
kinson Disease Genetics Collaboration. A standard clin-
ical evaluation involves a neurological examination, in-
cluding assessment by use of the Uniﬁed Parkinson’s
Disease Rating Scale (Fahn et al. 1987). Affected individ-
uals possessed at least two cardinal signs of PD (resting
tremor, bradykinesia, and rigidity). Rigorous clinical as-
sessment was performed by all participating clinicians to
provide a clear diagnosis of PD and to exclude any in-
dividuals that displayed atypical features of parkinsonism
(Scott et al. 2001). Unaffected participants demonstrated
no signs of the disease, and “unclear” participants showed
only one cardinal sign and/or atypical features. To main-
tain diagnostic consistency across participating clinics, a
clinical adjudication board consisting of a board-certiﬁed
neurologist with fellowship training in movement disor-
ders (B.L.S.), a dually board-certiﬁed neurologist and
Ph.D. medical geneticist (J.M.V.), and a certiﬁed physician
assistant (J.M.S.) reviewed the clinical data for all partic-
ipants. Parkin mutation carriers were excluded from this
study. All participants signed informed consents prior to
blood and data collection. Study protocols and consent
forms were approved by institutional review boards at
each participating center.
The families ( ) used in this association studyNp 644
were drawn from two data sets ascertained for genetic
studies of PD. The ﬁrst data set consists of singleton
families ( ), characterized by having only oneNp 355
sampled affected individual, with any number of unaf-
fected family members. The second data set consists of
multiplex families ( ), comprising nuclear fam-Np 289
ilies (families with at least two sampled affected siblings
and any number of unaffected individuals) or extended
pedigrees (families with at least two sampled affected
individuals who are not siblings or a parent-child pair,
with any number of unaffected individuals). For this
study, all subjects analyzed were white.
DNA Extraction and Genotyping
DNA samples were prepared and stored by the DCHG
DNA bank Core. Genomic DNA was extracted from
whole blood through use of the PureGene system (Gentra
Systems) with the Autopure LS. Primers and probes were
designed using the Primer Express 2.0 program (Applied
Biosystems). PCR ampliﬁcation was performed in 5-ml
reactions (3 ng dried DNA, 1# TaqMan universal PCR
master mix from Applied Biosystems, 900 nM of each
primer, and 200 nM of each probe) using GeneAmp PCR
system 9700 thermocyclers (Applied Biosystems) for a 40-
cycle program (50C for 2 min; 95C for 10 min; 40 #
[95C for 15 s, 60C for 1 min]). The ﬂuorescence gen-
erated during the PCR ampliﬁcation was detected using
the ABI Prism 7900HT sequence detection system and
was analyzed with SDS software (Applied Biosystems).
Stringent quality control measures were taken to ensure
data consistency. Internal controls consisted of 24 dupli-
cated individuals per 384-well plate. In addition, two sam-
ples from CEPH were plated eight times per plate to iden-
tify any Mendelian inconsistencies. All technicians were
blinded to these internal controls. Quality control samples
were compared in the Duke Center for Human Genetics
Data Coordinating Center. Data were stored and man-
aged by the PEDIGENE system (Haynes et al. 1995). To
pass quality control, data plates had to meet with 100%
matching for quality control samples and at least 95%
plate efﬁciency.
Statistical Analysis
A single affected and unaffected individual were se-
lected at random from each family, for tests of Hardy-
Weinberg disequilibrium. These tests were conducted
using Genetic Data Analysis software, applying a per-
mutation test with 3,200 permutations to estimate each
P value (Lewis Lab Software Web site). Two measures
of linkage disequilibrium (LD), squared correlation co-
efﬁcient (r2) and Lewontin’s standardized disequilibrium
coefﬁcient (D′), were computed between pairs of SNPs
through use of the Graphical Overview of Linkage Dis-
equilibrium (GOLD) software package (Abecasis and
Cookson 2000). Single-locus association analysis was
performed in the families through use of the pedigree
disequilibrium test (PDT) (Martin et al. 2000). We used
the PDTsum version of the statistic to compare allele
frequencies between affected individuals and their un-
affected parents (when available) or siblings within fam-
ilies (Martin et al. 2001). Similarly, single-locus genotype
frequencies were compared between affected individuals
and their parents or unaffected siblings within pedigrees
through use of the genotype PDT (geno-PDT) (Martin
et al. 2003). The multilocus geno-PDT was used to test
for association with disease, using genotypes jointly at
more than one locus (E.R.M., unpublished data). This
test can be used to dissect possible interactive effects
observed between alleles at multiple loci. Haplotype
analysis was conducted using the family-based associ-
ation test (FBAT) (Horvath et al. 2004). Haplotypeswith
frequencies !1% were not included in the analysis. The
empirical variance option of the FBAT programwas used
to ensure validity as a test of association in this linked
region.
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Figure 1 Gene structure of FGF20. Exons are denoted by blocks; coding regions are shown in gray, and UTRs are shown in white.
Locations of SNPs are indicated by arrows.
Table 1
Measures of Linkage Disequilibrium between FGF20 SNPs
ss20399076 rs1989756 rs1989754 rs1721100 ss20399075
ss20399076 … .086 .652 .045 .097
rs1989756 1 … .058 .018 .009
rs1989754 .986 1 … .268 .073
rs1721100 .315 .724 .943 … .259
ss20399075 .968 1 .961 1 …
NOTE.—r2 values are given above the diagonal, and D′ values are given below the
diagonal.
Bioinformatics
Sequence alignment of human and mouse FGF20 3′
UTR (GenBank accession numbers NM_019851 and
NM_030610, respectively) was performed using Clus-
talWmultiple sequence alignment software (Pearson and
Lipman 1988; Clustal W Web site). The alignment was
imported into GeneDoc version 2.6 for editing and shad-
ing (Nicholas et al. 1997; GeneDoc Home Page).
Results
To test the possible inﬂuence of FGF20 on risk of PD,
we ﬁrst sequenced four pools, each containing ﬁve un-
affected individuals, to screen exons and UTRs for poly-
morphisms (denoted throughout the article by their
dbSNP rs and ss numbers). No sequence variations were
discovered within exons. However, we discovered novel
polymorphisms within sequence upstream from exon 1
(ss20399076) and a 3′ UTR (ss20399075) SNP. We also
veriﬁed one 3′ UTR SNP (rs1721100) and two intronic
SNPs (rs1989754 and rs1989756) (ﬁg. 1). A total of 644
pedigrees including 3,655 individuals were genotyped in
this study. No mismatches of internal controls were re-
ported, and average plate efﬁciency was 98%.
All ﬁve SNPs tested showed no evidence for deviation
from Hardy-Weinberg equilibrium (data not shown).
The LD analyses based on r2 revealed strong LD be-
tween SNPs rs1989754 and ss20399076 and moderate
levels of LD between SNPs rs1721100 and rs1989754
and between rs1721100 and ss20399075 in the affected
individuals (table 1). Values of D′ were large for most
SNP pairs, suggesting that there has been little historic
recombination in the region over time. Levels of LD
were similar in the unaffected set (data not shown).
Table 2 shows single-locus results from the PDT. Sin-
gle-locus tests demonstrated strong evidence of associ-
ation of an intronic SNP, rs1989754 ( ; CPp .0006
allele positively associated), and a novel 3′ UTR SNP,
ss20399075 ( , T allele positively associated),Pp .0008
with risk of PD in the overall sample. Weaker evidence
of association was found between a second SNP located
within the 3′ UTR, rs1721100 ( ; C allele pos-Pp .02
itively associated), and risk of PD (table 2). Tests based
on individual genotypes demonstrated that genotypes
rs1989754CC ( ) and ss20399075CT (Pp .006 Pp
) increase risk. Global tests for genotype associ-.0004
ation also showed signiﬁcant results for rs1989754 and
ss20399075 (table 3).
The strongest associations were found with markers
rs1989754 and ss20399075; however, these markers
are in strong LD ( ), suggesting that little′D p 0.96
recombination has occurred between these SNPs over
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Table 2
Allele Frequencies and P Values of Single-Locus Association Analysis
SNP ALLELE
FREQUENCY AMONG FAMILIESa
( )Np 188
FREQUENCY IN
DISCORDANT SIBLINGSb
PDT
P VALUE
Parental
Transmissionsc
Parental
Nontransmissionsd
Affected
( )Np 553
Unaffected
( )Np 716
ss20399076A .476 .488 .514 .524 .1616
rs1989756A .077 .099 .080 .073 .3942
rs1989754C .617 .553 .597 .561 .0006
rs1721100C .323 .204 .307 .289 .0196
ss20399075T .114 .057 .107 .089 .0008
a Computed frequencies in families including parental and affected offspring genotypes.
b Computed frequencies from all affected and unaffected siblings.
c Frequencies among alleles transmitted from parents to affected offspring.
d Frequencies among alleles not transmitted from parents to affected offspring.
Table 3
Genotype PDT Results (Based
on Global Test) for FGF20
SNPs
SNP
GenoPDT
P VALUE
ss20399076 .4077
rs1989756 .4355
rs1989754 .0056
rs1721100 .0713
ss20399075 .0004
time. This high degree of LD complicates the inter-
pretation of the data as to whether independent or
interactive effects of these markers are being observed.
To test for independent effects of SNPs rs1989754 and
ss20399075, we removed all families carrying the pos-
itively associated ss20399075T allele from the data set.
The PDT was used to analyze SNP rs1989754 in the
remaining 316 families, consisting of 63 triads and 693
discordant sib pairs. This stratiﬁed analysis revealed
no signiﬁcant evidence of association for increased
risk of PD at rs1989754 when tested without the
ss20399075T-carrying families ( ). This suggestsPp .09
that, if rs1989754C has an effect on PD risk, it is an
interactive effect that occurs only the presence of the T
allele at ss20399075. The opposite stratiﬁed analy-
sis, removing all families carrying the high-frequency
rs1989754C allele, was not performed, since a large
proportion of families would have to have been re-
moved, thus reducing power in the analysis. The results
of the stratiﬁed analysis are further supported by the
joint (multilocus and haplotype) analysis of the SNPs.
FBAT was used to search for association of PD with
haplotypes that include the ﬁve genotyped SNPs. This
method estimated 18 possible haplotypes, but only 5
haplotypes were found at frequencies 11% in our sam-
ple. We observed that haplotype A-G-C-C-T is posi-
tively associated with risk of PD ( ), whereasPp .0003
haplotype A-G-G-G-C is negatively associated with risk
( ) (table 4). The global test that simulta-Pp .0009
neously tests whether any haplotype is associated with
disease also demonstrated that the haplotype effect is
highly signiﬁcant ( ). The combination of al-Pp .002
leles within haplotypes is congruent with the single-lo-
cus results, since the A-G-C-C-T haplotype carries risk
alleles ss20399075T and rs1989754C. Importantly, the
C allele at rs1989754 occurs on haplotypes with both
the C and T alleles at the ss20399075 locus, but only
the haplotype carrying ss20399075T shows signiﬁcant
positive association with PD risk.
Similarly, analysis of multilocus genotypes showed
signiﬁcant positive association only with carriers of
ss20399075T (table 5). In this genotypic analysis, how-
ever, we found that ss20399075CT was positively as-
sociated only in individuals homozygous for CC at
rs1989754. Despite the fact that a comparable number
of informative families were heterozygous for GC-CT,
this multilocus genotype showed no evidence for as-
sociation. This suggests a possible interactive effect be-
tween the rs1989754CC and ss20399075CT genotypes.
However, formal tests for interaction were not per-
formed, because of the diverse family structures and
high degree of LD between the SNPs.
Discussion
FGF20 and its family members are expressed in both
embryonic and adult tissues, suggesting that they are
critical factors in brain development and cell homeosta-
sis (Dono 2003). Studies have shown that FGF20 acts
as a neurotrophic factor in dopaminergic cells, substan-
tially enhancing their survival in culture (Ohmachi et al.
2000). This effect is mediated by the binding of FGF20
to its receptor, FGFR-1c, which activates the mitogen-
activated protein kinase pathway, resulting in the phos-
phorylation of extracellular regulated kinase (Ohmachi
et al. 2003). Given the role that FGF20 plays in the
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Table 4
Haplotype Analysis of FGF20
BASE AT SNP
NO. OF
FAMILIES FREQUENCY Za P VALUEbss20399076 rs1989756 rs1989754 rs1721100 ss20399075
A G G G C 228 .42 3.318 .0009
G G C G C 205 .21 .294 NS
G G C C C 179 .19 .691 NS
A G C C T 80 .08 3.587 .0003
G A C G C 89 .06 .465 NS
a Z p normal statistic.
b NS p not signiﬁcant; global test .Pp .002
Table 5
Multilocus Genotype PDT Analysis
GENOTYPE
FREQUENCY AMONG FAMILIES
( )Np 176
FREQUENCY IN
DISCORDANT SIBLINGS
Za P VALUEbrs1989754 ss20399075
Parental
Transmissions
Parental
Nontransmissions
Affected
( )Np 535
Unaffected
( )Np 694
GG CC .051 .073 .166 .194 2.480 .013
GG CT .000 .000 .001 .001 NA NA
GC CC .232 .267 .394 .412 .912 .362
GC CT .039 .022 .074 .072 .000 .946
CC CC .113 .102 .237 .224 .697 .486
CC CT .051 .034 .117 .089 2.785 .005
CC TT .011 .000 .007 .005 .810 .423
NOTE.—NA p not analyzed.
a Z p normal statistic.
b Global test .Pp .03
survival of dopaminergic neurons, FGF20 presents an
excellent candidate susceptibility gene for PD risk.
We demonstrated that one intronic SNP and two SNPs
located within the 3′ UTR of FGF20 are signiﬁcantly
associated with PD risk. Furthermore, haplotype A-G-C-
C-T, which carries the positively associated alleles of each
of these SNPs, signiﬁcantly increases risk of PD. Stratiﬁed
analysis and haplotype analysis suggest that rs1989754C
does not have an independent effect on risk; however, its
effect is observed in the presence of ss20399075T. Tests
for interaction between alleles at both loci cannot be
performed, since the ss20399075T allele occurs exclu-
sively with rs1989754C in our data set; ss20399075T
was not observed with the rs1989754G allele.
Taken together, the analyses suggest three possible
interpretations for the observed association of FGF20
polymorphisms with PD risk. First, the association may
be caused by the ss20399075T allele alone. Given the
location of ss20399075, we suggest that this polymor-
phismmay disrupt a regulatory binding sequencewithin
in the 3′ UTR and alter message expression. Therefore,
if an RNA-binding protein is unable to bind to the reg-
ulatory site of the 3′ UTR sequence, the FGF20 tran-
script stability, translation, or transport to subcellular
locations may be compromised (Conne et al. 2000).
The FGF20 3′ UTR sequence is largely conserved
between human and mouse (ﬁg. 2). SNP rs1721100
lies within a highly conserved segment of sequence but
is not homologous to mouse, whereas the C allele of
SNP ss20399075 is conserved between mouse and hu-
man. It is possible that the conservation of this region
may be important in message regulation and that the
ss20399075C/T change disrupts a binding site or cre-
ates a conformational change in the sequence.
A second possible interpretation of our results is that
the association between ss20399075T and risk is en-
hanced by rs1989754C. The haplotype analysis indi-
cates that A-G-C-C-T, which carries both risk alleles, is
strongly associated with PD risk. This analysis, as well
as the multilocus genotype test, suggests that these two
polymorphisms may be acting together to inﬂuence risk.
It is possible that both SNPs act in concert to regulate
transcription and expression of FGF20, although they
are located in two different gene regions. Alternatively,
these associated SNPs may be in LD with an untested
polymorphism, occurring on haplotype A-G-C-C-T, that
is associated with PD risk. To test these possibilities, mo-
lecular studies are needed to verify the effects of these
polymorphisms on the expression level of FGF20.
We have conducted several statistical tests and have
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Figure 2 Sequence alignment of human and mouse 3′ UTR sequences. Sequence homology is indicated by gray shading, dashes represent
insertions, and black boxes illustrate SNP locations.
not attempted to correct for multiple testing in this pre-
sentation. It is noteworthy that, even with a standard
Bonferroni correction for multiple tests at the ﬁve SNPs,
the single-locus P values for rs1989754 and ss20399075
are still signiﬁcant, with an experimentwise signiﬁcance
of .05. A less conservative approach is to use the false
discovery rate (Benjamini and Hochberg 1995). With
this adjustment, under the assumption that no SNP
is associated with disease ( ), polymorphismsap 0.05
rs1989754, rs171100, and ss20399075 are all still con-
sidered signiﬁcant. This further supports the signiﬁcance
of our ﬁndings.
Studies have shown clearly that FGF20 is critical in
the survival of dopaminergic neurons within the sub-
stantia nigra; however, the mechanistic process of this
protective action and its regulation has not yet been
elucidated. A recent study has shown that the protective
effect of the related FGF2 polypeptide acts with glial-
cell-line–derived neurotrophic factor (GDNF) to pro-
mote repair of lesioned hippocampal cells (Lenhard et
al. 2002). GDNF is also a key neurotrophic factor that
is important in the maintenance and development of
dopaminergic neurons (Lin et al. 1993). Expression lev-
els of FGF20 may be vital to a signaling cascade in-
volved in the repair of damaged dopaminergic neurons.
We have demonstrated that polymorphisms in FGF20
are strongly associated with increased risk of PD, as
observed in parental transmission of alleles to affected
offspring and transmissions of alleles in phenotypically
discordant sib pairs. We have also demonstrated that
an allelic combination in a haplotype signiﬁcantly in-
ﬂuences PD susceptibility.We suggest that the associated
polymorphisms may affect regulation of FGF20 ex-
pression and thereby inﬂuence PD pathogenesis. Mo-
lecular studies are under way to verify the causative role
of ss20399075 and rs1989754 SNPs and whether
these polymorphisms impact PD risk independently or
collectively.
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